DTX-101

DTX-101 is a preclinical-stage bispecific antibody being developed by Dualitas Therapeutics (formerly Dual Therapeutics) for the treatment of autoimmune diseases, with a specific focus on Celiac Disease. The molecule was discovered using the company's proprietary DualScreen™ Bispecific Discovery Engine, a platform designed to identify bispecific antibodies with favorable drug-like properties and therapeutic potential. While the specific molecular targets and mechanism of action have not been publicly disclosed, DTX-101 is engineered to address the complex immune dysregulation associated with autoimmune conditions through its dual-targeting capabilities. The program is currently in the lead generation and optimization phase of development.